Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients

Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy ((177)Lu-PSMA RLT) is an effective salvage treatment. However, studies have highlighted haematologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kesavan, Murali, Meyrick, Danielle, Gallyamov, Marat, Turner, J. Harvey, Yeo, Sharon, Cardaci, Giuseppe, Lenzo, Nat P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001812/
https://www.ncbi.nlm.nih.gov/pubmed/33799431
http://dx.doi.org/10.3390/diagnostics11030515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001812/
https://www.ncbi.nlm.nih.gov/pubmed/33799431
http://dx.doi.org/10.3390/diagnostics11030515

Ejemplares similares